ESR1 and systemic sclerosis: In the same vein, Mathian and coworkers [23] found higher levels of aTreg in SSc patients with the diffuse and/or active disease (here demonstrated to be also, in large part, anti-ERα positive) suggesting a compensatory, but inefficient, amplification of regulatory cells in the context of active inflammation.